About EuroStemCell

IMBA

Jürgen Knoblich is Deputy Director and a Senior Scientist at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA). In 2009 he was awarded the Wittgenstein Prize for his work on asymmetric cell division.

Center for Regenerative Medicine University of Modena and Reggio Emilia

Professor De Luca, and his principal collaborator Graziella Pellegrini, have been involved in epithelial stem cell biology aimed at clinical application in regenerative medicine for over 20 years. Beside his work on the use of human epidermal stem cell cultures in life-saving treatment of massive full-thickness burns and in repigmentation of stable vitiligo and piebaldism, he established human limbal stem cell culture aimed at corneal regeneration in patients with severe limbal stem cell deficiency. This treatment leads to recovery of vision in patients with poor alternative options for therapy. Michele De Luca is currently coordinating the first (successful) ex-vivo epithelial stem cell-mediated gene therapy clinical trial for the gene therapy of junctional epidermolysis bullosa, a serious genetic skin disease. He is also studying molecular mechanisms regulating self-renewal, proliferative potential and clonal evolution of epithelial stem cells.

Read an interview with Michele De Luca.

Daniel Besser studied biology at the Freie Universität Berlin and obtained his diploma in 1990. He received his PhD in 1996 from the university of Basel with a thesis from the Friedrich-Miescher-Institute, Basel on signal transduction in the gene regulation of urokinase-type plasminogen activator. He worked at Rockefeller University, New York until 2004 in the laboratories of Hidesaburo Hanafusa and James E. Darnell on Stat3 signaling and the function of c-Src; and from 2002 on pluripotency in embryonic stem cells in the lab of Ali H. Brivanlou. He has been leader of a research group at the Max-Delbrück-Center for Molecular Medicine in Berlin until 2011 focusing his research on signal transduction mechanisms in human and murine embryonic stem cells.

Since 2012 he is managing director of the German Stem Cell Network (GSCN). The GSCN is fostering national and international scientific communications, as well as developing outreach programs for schools and the general public in Germany.

The Tajbakhsh group focuses on identifying and characterising skeletal muscle stem cells. They use a genetic approach to examine how skeletal muscle stem cells are born, and how they acquire their identity. They also investigate the cell division mechanisms that govern self-renewal and differentiation during embryonic development and in the adult. They are able to isolate skeletal muscle stem cells for potential therapies using engineered fluorescent markers.

Wendy Bickmore is Director of the MRC Human Genetics Unit, part of the MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh.  After an undergraduate degree in Biochemistry at Oxford, she obtained her PhD at Edinburgh University.  During postdoctoral training, she became fascinated by the structure and organization of chromosomes in the nucleus and as an independent fellow of the Lister Institute of Preventive Medicine (1991-1996) she went on to show that different human chromosomes have preferred positions in the nucleus, related to their gene content. As an MRC group leader she then investigated how individual genes are organized and packaged in the nucleus and how they move in the cell cycle and during development. Current research in Wendy Bickmore’s laboratory focuses on how the spatial organization of the nucleus influences genome function in development and disease. Wendy is an EMBO member and a Fellow of the Royal Society of Edinburgh and of the Academy of Medical Sciences. She is an editor on many journals including PLoS Genetics and Cell and is the President-Elect of the Genetics Society.

Usher Institute for Population Health Sciences and Informatics

Sarah Chan is a recently-appointed Chancellor’s Fellow at the Usher Institute for Population Health Sciences and Informatics, University of Edinburgh. She was educated at the University of Melbourne, Australia, where she completed degrees in biological science and in law, and spent a number of years as a researcher in a molecular biology laboratory before moving to work in the area of science policy and stem cell ethics. In 2005 Sarah took up a Research Fellowship in Bioethics and Law at the Centre for Social Ethics and Policy, University of Manchester, where she also completed a MA in Health Care Ethics and Law and a PhD in Bioethics. From 2009 to 2015 she was Deputy Director of the Institute for Science, Ethics and Innovation, University of Manchester. Her research interests and publications cover areas including the ethics of gene therapy and genetic information, enhancement, research ethics, stem cells, animal ethics, transhumanism, and the ethics of science and innovation.

Faculty of Medicine, Lund University, Sweden

Göran Hermerén has been Professor of Medical Ethics at the Faculty of Medicine, Lund University, Sweden, since 1991. He has also held the position of Professor of Philosophy, Lund University, since 1975 and he was Professor of Philosophy of Science and Humanities, Umeå University from 1970-75. He is co-ordinator of the EU-funded research project Europriorities and is involved in several other EU-funded projects. He has published and edited books on research ethics as well as papers on ethical problems (mainly medical ethics) in international periodicals. Current research and teaching interests include ethical aspects of gene testing and stem cell research.

Freddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences.

Philip Newsome is Professor of Experimental Hepatology and Clinical Director of the Birmingham University Stem Cell Centre. He is an Area Lead (Liver Regeneration) in the NIHR Birmingham Liver Biomedical Research Unit.

Philip has published over major research papers in scientific journals as well as reviews and book chapters in the fields of stem cell biology and liver disease. He has received major grants from NIHR, European Union, Wellcome Trust, UKSCF, BBSRC and the Medical Research Council.

He is an enthusiastic communicator on the theme of translational stem cell work and non-alcoholic fatty liver disease and gives frequent talks to various groups at both the local and national level. Philip frequently contributes to both the local and national media and continues to advise the BBC on stem cell-related stories.

Centre for Genomic Regulation, Barcelona

Thomas Graf is Coordinator of the Differentiation and Cancer Programme at the Center for Genomic Regulation and an ICREA professor in Barcelona, Spain. His lab is interested in the role of transcription factors in hematopoiesis and leukemia, and how these regulators can induce trans-differentiation. Is blood cell differentiation a strictly hierarchical process or does more than one pathway exist for the formation of a given cell type? More specifically, how does a single transcription factor, C/EBPa, reprogram B-lymphocytes to become functional macrophages? During this process, what epigenetic changes are required to turn thousands of genes off and on, making a 'cell within a cell'? What are the common principles during induced transdifferentiation? Answering some of these questions will enhance our understanding of the connection between differentiation and cancer. They will also help designing new protocols for the controlled reprogramming of differentiated cells that might be useful for cell replacement therapies.



Read an interview with Thomas Graf by Monya Baker of Nature Stem Cell Reports (requires subscription): Cellular Identity and Transdifferentiation

Centre for Stem Cell Biology, University of Sheffield

Prof. Andrews is Co-Director of the Centre for Stem Cell Biology at the University of Sheffield and leader of its Stem Cells and Cancer research group. The appearance of genetically abnormal cells aising from pluripotent stem cells in culture offers a unique model to study the initiation and progression of cancer cells. These models will allow the identification of critical genes which are responsible for the cancer-like properties of cells and may lead to novel strategies and therapies for treatment.

Petr Dvorak is Professor in Cellular and Molecular Biology and Genetics Department of Biology, Faculty of Medicine, Masaryk University.

Professor Andrew Webster has been Professor in the Sociology of Science and Technology at York since 1999. He is also the Director of the Science and Technology Studies Unit at York which he established originally at Anglia Ruskin University in 1988. He has held a visiting fellowships at ANU, Sydney and Gothenburg universities.

He was Head of the Department of Sociology at York between 2004-9 and then Dean of Social Sciences and member of the University's Senior Management Group until 2013.He has directed national research programmes for the ESRC and MRC in the fields of emerging health technologies and stem cells, and held major grants from UK research councils and the European Commission.

He was elected Fellow of the Academy of Social Science in 2007.

Andrew serves on a number of editorial and scientific advisory boards as well as national policy committees including the UK Stem Cell Bank Steering Committee, the Regenerative Medicine Expert Group Sub-committee, and the Scientific Advisory Committee, Pharmacy Research UK, as well as member of various UK and international academic bodies including, the BSA, EASST, and the Dutch WTMC's International Scientific Board.